Related Experiment Videos
Phenylbutazone: factors influencing plasma concentrations
The Journal of International Medical Research
|January 1, 1977
Summary
Phenylbutazone metabolism in humans is partially understood. However, differences in its half-life after single versus multiple doses require further investigation to explain.
Area of Science:
- Pharmacokinetics
- Drug Metabolism
- Human Physiology
Background:
- Phenylbutazone is a nonsteroidal anti-inflammatory drug (NSAID).
- Understanding its metabolic fate and elimination is crucial for safe and effective therapeutic use.
- Previous studies have provided insights into phenylbutazone's metabolic pathways in humans.
Purpose of the Study:
- To investigate discrepancies in phenylbutazone's half-life between single and multiple dosing regimens.
- To identify the underlying mechanisms limiting plasma concentrations with increased phenylbutazone doses.
Main Methods:
- Analysis of plasma phenylbutazone concentrations following single and multiple oral doses.
- Pharmacokinetic modeling to determine half-life and other relevant parameters.
Main Results:
- Observed significant differences between single and multiple dose phenylbutazone half-lives.
- Data suggests a saturation or limiting mechanism affecting phenylbutazone plasma levels at higher doses.
Conclusions:
- The complete metabolic fate of phenylbutazone in humans is not fully elucidated.
- Further research is necessary to understand the mechanism responsible for limiting phenylbutazone plasma concentration during dose escalation.